Labiotech.eu

News and Trends 16 Oct 2015

Bavarian Facility can now grow Global Strains of Algae for Aerospace Biofuel Production

The Technology University of Munich (TU München) has built a unique global-climate simulating Algal plant on the Ludwig Bölkow Campus in Ottobrunn (Bavaria). Able to cultivate algal strains from all over the world, the research team hopes this will allow them to study and discover new types to be exploited by Biotechs for biofuel production, […]

October 16, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 16 Oct 2015

Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

This week, we’re leaving Paris and heading East to a city that’s 9 times bigger than the capital of France, it’s also the city we all call home here at Labiotech, Berlin. When someone thinks of Berlin, they think of the wall, the Fernsehturm (television tower) and its amazing nightlife (I can personally agree with this 😉 […]

October 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease. Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

New Oncology from Cologne (Germany) is a biotech which today published a paper in Nature on tumor-profile recognition of cancer of the sympathetic nervous system (Neuroblastoma) in conjunction with the latest research at the University of Cologne. The research team has found a new way to diagnose infants with the deadly high-risk version of Neuroblastoma, which […]

October 14, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

No, Novartis and Roche won’t merge (yet)!

Novartis already owns 33% of Roche, but even if both companies are headquartered in the same city of Basel (Switzerland), they still have no plans to merge. Joerg Reinhardt, The Chairman of Novartis – the second biggest Pharma company worldwide by market cap (€212Bn – J&J: €231Bn), was asked about it on the Swiss TV Bilanz […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Oct 2015

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

The Hemophilia Aid Program has just touched down the first batch of treatments in its target developing countries, as part of a 10-year commitment from US Biogen (Massachusetts) and Swedish Orphan Biovitrum AB (SOBI) from Stockholm via the World Federation of Hemophilia (WFH)’s AID project. The relief effort pledges to ship over 1 billion units […]

October 13, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 13 Oct 2015

Why can’t Novartis Commit to the Israeli Biotech Scene?

Novartis, the Swiss Acquisition-Giant from Basel, has once again taken bought a small chunk of shares from the Israel biotech scene for only $15M (2.5%), instead of making a final solid purchase. The Jerusalem biotech Gamida Cell, which has a stem-cell therapies for hematological diseases (leukemia and various types of anemia), was underwhelmed a second […]

October 13, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 13 Oct 2015

The Top 15 European Biotech VCs

Biotech wouldn’t exist without Venture Capitalists. These investors bring the cash necessary to run clinical trials or conduct the scaling-up of processes, along with many years of experience. Though admittedly Europe definitely hasn’t got as much money floating around as the US, there are many major Biotech VCs in Europe … Here are 15 of […]

October 13, 2015 - 9 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Bavarian Facility can now grow Global Strains of Algae for Aerospace Biofuel Production

Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

Innate Pharma receives $5M from its Monster-deal with BMS

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

No, Novartis and Roche won’t merge (yet)!

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

Why can’t Novartis Commit to the Israeli Biotech Scene?

The Top 15 European Biotech VCs

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!